Brno Showcased Its Strength in Precision and Personalised Medicine to European Partners

The Brno programme made it clear that precision medicine in the city is not built on vision alone, but on concrete programmes already delivering value for patients. Throughout the visit, delegates were introduced to a model based on close cooperation between University Hospital Brno, the Faculty of Medicine of Masaryk University, CEITEC MU and the Centre of Excellence CREATIC. This collaborative framework was highlighted by organisers and host institutions as one of the defining strengths of Brno’s approach.

A series of presentations showed how clinical care, research and advanced therapies are being linked in practice. Jaroslav Štěrba presented personalised treatment for paediatric oncology patients, Regina Demlová outlined the role of the CREATIC Centre of Excellence in advanced therapy medicinal products for children with serious, rare or undiagnosed diseases, and Aleš Hampl demonstrated how tissue engineering research is helping create the foundation for future personalised treatment approaches. Ondřej Slabý placed these topics into the broader context of the development of precision medicine in the Czech Republic and the long term cooperation among Brno’s leading institutions.

For CREATIC, the visit was an important opportunity to show how advanced therapies can become an integral part of a broader precision medicine ecosystem. The discussions illustrated that bringing innovation closer to patients requires more than scientific excellence alone. It also depends on long term infrastructure, translational capacity, strong clinical partners and the ability to connect discovery, development and implementation in one coherent pathway. This was one of the key messages of the Brno programme as presented to the international delegation.

Together, the presentations and site visit positioned Brno as a place where top level research, clinical practice and advanced therapeutic development meet with a shared ambition to move personalised medicine closer to patients. The broader Prague conference had marked ten years of coordinated European support for personalised medicine, while the Brno visit offered a practical demonstration of how that vision can be translated into real structures, partnerships and patient oriented programmes.

For CREATIC, being part of this presentation of Brno to European partners was also a reminder that advanced therapies are becoming an increasingly visible part of the region’s contribution to the future of personalised medicine. In this sense, Brno is not only participating in the European discussion, but helping shape it through concrete cooperation between research, healthcare and innovation.